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Abstract: A short sequential synthesis of pyrrolidino- pyridines and pyrimidines illustrates 
the potential of combining Ugi-Smiles couplings with radical tin-free processes. 
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1. Introduction 
Among multi-component reactions (MCRs), the Ugi reaction has a privileged position due to its 
broad synthetic significance [1,2]. Its four points of diversity combined with possible further 
transformations of the resulting adducts have became very popular in heterocyclic synthesis. Indeed, 
the Ugi reaction has been associated with a wide range of post-condensation reactions in order to form 
even more complex scaffolds, including cycloadditions [3-9], metal-catalyzed processes [10-15] and 
cyclocondensations [16-21]. Among this very impressive bibliography, the combination of Ugi or 
Passerini reactions with radical chemistry has been scarcely documented [22-27]. Among the various 
radical systems explored in our group, we have mostly studied the potential of xanthate radical transfer 
resulting in various cyclizations of Ugi xanthate adducts bearing suitable alkene [22], alkyne [25] or 
aryl [26] moieties. In all these examples, α-chloroacetic acid was used as the acidic partner to 
introduce the xanthate moiety via a nucleophilic substitution. However, these intramolecular  
post-condensations did not exploit the full potential of the xanthate radical transfer. Indeed, compared 
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to tin hydride chemistry, the reversible nature of the addition of radicals onto the thiocarbonyl group is 
associated with high yielding intermolecular couplings between xanthates and alkenes [28,29]. Herein, 
we propose to explore this feature and to further increase the molecular diversity of the Ugi step 
through a xanthate triggered addition/cyclization cascade to form new heterocyclic systems (Scheme 1). 
Scheme 1. Synthetic strategy towards pyrrolidino fused systems. 
 
2. Results and Discussion 
Developing the radical chemistry of xanthates, the Zard group has reported various synthetic 
approaches towards fused cyclic systems such as indanes, indolines or azaindolines [30-35]. These 
syntheses feature an intermolecular addition of a xanthate on an alkene followed by an intramolecular 
trapping with a suitably positioned aryl group. As part of our ongoing interest in Ugi-type reactions, 
we naturally imagined to synthesize the radical acceptor through a Ugi-Smiles coupling. Indeed, we 
recently developed the use of electron-deficient phenols as acid surrogates in Ugi reactions to form  
N-arylamino carboxamides [36,37]. The use of a partner substituted with an alkene, such as allylamine, 
in this reaction would afford in one step an interesting substrate to test the tandem radical process 
(Scheme 1). Concerning the phenol, most reported Ugi-Smiles couplings involve a nitro group to 
perform the Smiles rearrangement. As nitroaryl derivatives are often associated with inhibition of 
radical chain processes, we prefer the use of hydroxy heterocycles (pyridines, pyrimidines) which also 
led to efficient multicomponent couplings [38]. N-allylaminopyridines and N-allylaminopyrimidines 
are known to react with xanthate under radical conditions, however the scope of these reactions seems 
to be limited by the nucleophilic behavior of the cyclic nitrogen atom. Indeed all reported radical 
tandem were performed on 2- or 5-halosubstituted heterocycles (chloro and fluoro) in order to lower 
the reactivity at the nitrogen center (Scheme 2) [31-35]. 
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Scheme 2. Selected examples from Zard’s group [31,33]. 
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2.1. Four-Component Coupling Towards Radical Substrates 
Various Ugi-Smiles adducts were thus prepared starting with allylamine as the amine partner. The 
latter was coupled with different hydroxy- pyridines and pyrimidines. The MCR coupling was 
performed under classical conditions using methanol as solvent. The starting radical substrates were 
obtained in modest to good yields. 
Table 1. Preparation of the radical substrates. 
 
Entry R1 R2 R3 R4 Y Z 
Product 
(%) 
1 Et Cy Me Me N N 1a (38%) 
2 i-Bu Cy H H N CH 1b (69%) 
3 i-Bu t-Bu H H N CH 1c (43%) 
4 Et Cy Ph Me N N 1d (61%) 
5 H p-MeBn Ph Me N N 1e (60%) 
6 Et Cy H H CNO2 N 1f (41%) 
7 i-pr p-ClBn Me Me N N 1g (68%) 
2.2. Radical Cascade 
In previous studies on xanthate additions on N-allylamino- pyridines and pyrimidines, a first  
1,2-addition product on the alkene could be obtained and isolated under heating with substoichiometric 
amounts of a radical initiator such as dilauroyl peroxide (DLP) in refluxing 1,2-dichloroethane (DCE) 
or ethyl acetate. Then the intermediate adducts could cyclize under treatment with further DLP or  
di-tert-butyl peroxide (more than 1 equivalent) at higher temperature allowing cleaner reactions (Scheme 3). 
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Even if the yields are expected to be lower, we preferred to perform the cascade under a single set of 
experimental conditions in order to keep the multicomponent sequence as short as possible. When 
adduct 1a was refluxed in DCE (0.2 M) with DLP added in 15 mol% portions every twenty minutes, 
we could isolate the desired cyclized pyrrolidine 2a as a 9:1 mixture of diastereomers [39] in 48% 
isolated yield, after overall addition of 1.5 equivalent of DLP (Scheme 3). 
Scheme 3. Radical reaction conditions. 
 
This sequence is initiated by decomposition of the xanthate into the electrophilic radical I, which is 
then trapped by the alkene moiety to give intermediate II. The latter is an electron-rich radical that can 
react with the starting xanthate to form intermediate IV. The latter being slightly less reactive than the 
starting xanthate towards radicals issued from DLP, accumulates in the medium and reacts when 
further amount of DLP is added without much 1 left to enter in the chain process. After addition of the 
radical onto the aryl ring, the intermediate species III further aromatize through interaction with the 
DLP (Scheme 4). 
Scheme 4. Plausible mechanism. 
 
To evaluate the scope of this cyclization, the reaction was performed with the Ugi-Smiles adducts 
formerly prepared and the results are displayed in Table 2. 
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Table 2. Radical additions-Cyclizations. 
 
Entry Ugi-Smiles adduct Xanthate Cyclized product Yield (%) 
1 
1b 
 
2b (dr 4:1) 
24 
2 
1c 
 
2c (dr 2:1) 
27 
3 
1d 
 
2d (dr 2.3:1) 
55 
4 
1d 
 
2e (dr 1.5:1) 
44 
5 
1e 
 
2f 
27 
6 
1f 
 
2g (dr 3:1) 
48 
7 
1a 
 
2h (dr 4:1) 
34 
8 
1g 
 
2i (dr 2.3:1) 
43 
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Pyridines and pyrimidines without any halogen substitutent at the 2 or 5 position can act as radical 
trapping agents in this sequence. In the study disclosed by Zard, initial attempts with 2-aminopyridine 
or 2-amino-5-methylpyridine as starting materials led to successful 1,2-addition product with the 
xanthate, but no indolizine could be formed in the following cyclization step [31]. Chloro or fluoro 
substituents are expected to lower the electron density in the aromatic ring leading to easier addition of 
the nucleophilic intermediate radical species, and this may explain the moderate yields observed. In 
our case, the reaction turns out to be poorly efficient with 4-aminopyridines, with yields not exceeding 
30% (Table 2, Entries 1–2), a nitro group at the 5-position of the 2-aminopyridine ring activates the 
cyclization as a higher 48% isolated yield could be obtained (Table 2, Entry 6). Pyrimidines, in 
agreement with their higher electrophilicity, are better partners, giving yields over 50% with simple 
alkyl or aryl susbtituents on the heterocyclic core (Table 2, Entry 3). 
3. Experimental 
3.1. General 
1
H-NMR spectra were recorded on a 400 MHz spectrometer (Bruker Avance 400), using CDCl3 
solvent as reference and/or internal deuterium lock. 
13
C-NMR spectra were recorded on a 100.6 MHz 
spectrometer (Bruker Avance 400). Two-dimensional NMR spectroscopy [
1
H -
1
H COSY spectra,  
1
H - 
13
C COSY spectra (HSQC) and long-range 
1
H -
13
C COSY spectra (HMBC)], were carried out to 
determine the correlation between 
1
H and 
13
C. The chemical shifts for all NMR spectra are expressed 
in parts per million to high frequency of TMS reference. Coupling constants (J) are quoted in Hz and 
are recorded to the nearest 0.1 Hz. The IR spectra were obtained using ATR accessories on a Bruker 
Tensor 27 instrument. High-resolution (HR) mass spectra were recorded on a Hewlett-Packard HP 
5989B spectrometer. TLC was carried out using precoated plates of silica gel 60F254 (SDS-Carlo-Erba). 
3.2. Ugi-Smiles Coupling Procedure 
To a 1 M solution of hydroxyheteroaromatic compound in methanol were added successively  
1.0 equivalent of amine, 1.0 equivalent of aldehyde and 1.0 equivalent of isocyanide. The resulting 
mixture was stirred at 65 °C for 18–36 h. The solvent was removed afterwards under reduced pressure 
to afford the Ugi-Smiles product after purification by flash chromatography on silica gel. 
3.3. DLP-Cyclisation Reaction Procedure 
A solution of Ugi-Smiles adduct (1.0 mmol) and xanthate (1.2 mmol) in 1,2-dichloroethane (1.0 M) 
was reﬂuxed for 5 min under argon before DLP was added (60 g, 0.15 mmol) from the top of the 
condenser. Portions of DLP (60 mg, 0.15 mmol) were added every 20 min until complete 
disappearance of Ugi-Smile adduct and the starting xanthate, then the remaining DLP was added every 
20 min until complete disappearance of the intermediate (TLC monitoring). Concentration under 
reduced pressure aﬀorded an oily pale brown residue, which was purified by ﬂash chromatography 
eluting with petroleum ether/diethyl ether to give the pure product as a mixture of two diastereomers. 
In all the cases, the spectral data are given for the major diastereomer. 
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2-(N-Allyl-N-(2,6-dimethylpyrimidin-4-yl)amino)-N-cyclohexylbutanamide (1a). Yellow solid, (1.0 gm, 
38%), mp 124–125 °C; 
1
H-NMR: δ (ppm) 6.69 (br s, 1H), 6.11 (s, 1H), 5.86–5.69 (m, 1H), 5.27–5.01 
(m, 3H), 4.08 (dd, 1H, J = 4.8, 17.0 Hz), 3.84 (d, 1H, J = 17.0 Hz), 3.75–3.63 (m, 1H), 2.51 (s, 3H), 
3.32 (s, 3H), 2.13–2.00 (m, 1H), 1.92–1.81 (m, 1H), 1.78–1.59 (m, 3H), 1.58–1.46 (m, 2H), 1.40–1.22 
(m, 2H), 1.20–1.06 (m, 2H), 1.02–0.93 (m, 1H), 0.90 (t, 3H, J = 7.3 Hz); 
13
C-NMR: δ (ppm) 170.1, 
166.1, 165.3, 162.6, 133.5, 116.9, 100.3, 58.8, 47.6, 47.3, 32.9, 32.7, 26.1, 25.5, 24.5, 24.4, 24.3, 21.9, 
10.9; IR (thin film): 2929, 2855, 2356, 1657, 1583, 1539, 1479, 1448, 1403, 1343, 1273, 1177, 1089 cm
−1
; 
HRMS: Calcd. for C19H30N4O: 330.2420, Found: 330.2425. 
2-(N-Allyl-N-(pyridin-4-yl)amino)-N-cyclohexyl-4-methylpentanamide (1b). Pale yellow solid,  
(475 mg, 69%), mp 110–111 °C, 
1
H-NMR: δ (ppm) 8.23 (dd, 2H, J = 1.6, 5.2 Hz), 6.59 (dd, 2H,  
J = 1.6, 5.2 Hz), 5.95–5.80 (m, 2H), 5.29–5.21 (m, 2H), 4.25 (t, 1H, J = 6.9 Hz), 4.00 (dd, 1H, J = 5.2, 
17.2 Hz), 3.90 (dd, 1H, J = 5.2, 17.2 Hz), 3.80–3.69 (m, 1H), 2.08–2.00 (m, 1H), 1.86–1.76 (m, 2H), 
1.70–1.53 (m, 5H), 1.39–1.25 (m, 2H), 1.15–1.00 (m, 3H), 0.92 (d, 3H, J = 6.7, Hz), 0.90 (d, 3H,  
J = 6.7 Hz); 
13
C-NMR: δ (ppm) 169.9, 153.0, 150.2, 133.2, 118.1, 108.3, 61.0, 49.7 , 48.4, 37.7, 32.9, 
25.4, 25.2, 24.7, 22.9, 22.1; IR (thin film): 2930, 2853, 1652, 1596, 1544, 1513, 1450, 1235, 1169 cm
−1
; 
HRMS: Calcd. for C20H31N3O: 329.2467, Found: 329.2467. 
2-(N-Allyl-N-(pyridin-4-yl)amino)-N-tert-butyl-4-methylpentanamide (1c). Pale yellow solid, (360 mg, 
43%), mp 111–112 °C, 
1
H-NMR: δ (ppm) 8.25 (dd, 2H, J = 1.6, 5.0 Hz), 6.59 (dd, 2H, J = 1.6, 5.0 Hz), 
5.90–5.80 (m, 2H), 5.28–5.19 (m, 2H), 4.19 (dd, 1H, J = 5.9, 8.0 Hz), 4.00 (ddt, 1H, J = 1.5, 5.0,  
17.2 Hz), 3.89 (ddt, 1H, J = 1.5, 5.0, 17.2 Hz), 2.04–1.95 (m, 1H), 1.65–1.53 (m, 2H), 1.27 (s, 9H), 
0.91 (d, 3H, J = 6.6 Hz), 0.89 (d, 3H, J = 6.6 Hz); 
13
C-NMR: δ (ppm) 170.0, 153.0, 149.8, 133.1, 
117.9, 108.3, 61.4, 51.4, 49.6, 37.5, 28.5, 25.0, 22.8, 22.2; IR (thin film): 2964, 2930, 2871, 1676, 
1596, 1544, 1513, 1454, 1367, 1266, 1231, 1172 cm
−1
; HRMS: Calcd. for C18H29N3O: 303.2311, 
Found: 303.2309. 
2-(N-Allyl-N-(6-methyl-2-phenylpyrimidin-4-yl)amino)-N-cyclohexylbutanamide (1d). white solid, 
(600 mg, 61%), mp 114–115 °C, 
1
H-NMR: δ (ppm) 8.50–8.27 (m, 2H), 7.60–7.38 (m, 3H), 6.60 (br s, 
1H), 6.24 (s, 1H), 5.94–5.76 (m, 1H), 5.42–5.03 (m, 3H), 4.11 (d, 1H, J = 17.0 Hz), 3.96 (d, 1H,  
J = 17.0 Hz), 3.77–3.61 (m, 1H), 2.45 (s, 3H), 2.24–2.08 (m, 1H), 1.89–1.74 (m, 2H), 1.68–1.36 (m, 
4H), 1.33–1.13 (m, 2H), 1.04–0.80 (m, 6H); 
13
C-NMR: δ (ppm) 170.2, 166.0, 162.8, 162.6, 138.2, 
133.5, 130.2, 128.4, 127.9, 117.1, 101.3, 59.7, 47.7, 32.8, 32.6, 25.3, 24.6, 24.4, 24.3, 21.6, 11.1; IR 
(thin film): 2929, 2850, 1658, 1591, 1570, 1526, 1474, 1443, 1377, 1260, 1208, 1181, 1024 cm
−1
; 
HRMS: Calcd. for C24H32N4O: 392.2576, Found: 392.2575. 
2-(N-Allyl-N-(6-methyl-2-phenylpyrimidin-4-yl)amino)-N-p-tolylmethan-acetamide (1e). white solid, 
(498 mg, 60%), mp 124–125 °C, 
1
H-NMR: δ (ppm) 8.43–8.24 (m, 2H), 7.52–7.35 (m, 3H), 7.02 (d, 
2H, J = 8.0 Hz), 6.94 (d, 2H, J = 8.0 Hz), 6.79 (br s, 1H), 6.25 (s, 1H), 5.91–5.80 (m, 1H), 5.31–5.14 
(m, 2H), 4.39 (s, 2H), 4.29 (s, 2H), 4.16 (s, 2H), 2.44 (s, 3H), 2.25 (s, 3H); 
13
C-NMR: δ (ppm) 169.5, 
166.4, 163.3, 162.1, 137.9, 136.9, 134.7, 131.3, 130.2, 129.2, 128.2, 128.0, 127.3, 117.8, 99.9, 52.2, 
51.4, 42.9, 24.5, 21.0; IR (thin film): 2920, 2356, 1653, 1591, 1570, 1531, 1496, 1439, 1408, 1374, 
1260, 1230, 1194, 1068, 1024 cm
−1
; HRMS: Calcd. for C24H26N4O: 386.2107, Found: 386.2104. 
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2-(N-Allyl-N-(5-nitropyridin-2-yl)amino)-N-cyclohexylbutanamide (1f). Yellow solid, (508 mg, 41%), 
mp 111–112 °C, 
1
H-NMR: δ (ppm) 9.04 (d, 1H, J = 2.2 Hz), 8.21 (dd, 1H, J = 2.2, 9.4 Hz), 6.52 (d, 
1H, J = 9.4 Hz), 6.18 (br s, 1H), 5.87–5.72 (m, 1H), 5.38-5.11 (m, 3H), 4.23 (dd, 1H, J = 4.8, 17.0 Hz), 
4.03 (d, 1H, J = 17.0 Hz), 3.78–3.66 (m, 1H), 2.19–2.03 (m, 1H), 1.96–1.83 (m, 1H), 1.80–1.49 (m, 
5H), 1.43–1.22 (m, 2H), 1.21–1.06 (m, 2H), 1.05–0.88 (m, 4H); 
13
C-NMR: δ (ppm) 169.2, 160.7, 
145.6, 132.9, 132.7, 126.7, 117.6, 106.7, 60.0, 48.0, 47.9, 32.9, 32.8, 25.4, 24.5, 21.9, 10.8; IR (thin 
film): 2924, 2850, 1657, 1588, 1570, 1496, 1413, 1325, 1286, 1251, 1111 cm
−1
; HRMS: Calcd. for 
C18H26N4O3: 346.2005, Found: 346.2016. 
N-(4-Chlorobenzyl)-2-(N-allyl-N-(2,6-dimethylpyrimidin-4-yl)amino)-3-methylbutanamide (1g). White 
solid, (2.1 gm, 68%), mp 97–98 °C, 
1
H-NMR: δ (ppm) 7.23 (d, 2H, J = 8.2 Hz), 7.07 (d, 2H,  
J = 8.2 Hz), 6.13 (s, 1H), 5.70–5.55 (m, 1H), 5.13 (d, 2H, J = 13.3 Hz), 4.91 (br s, 1H), 4.40–4.25 (m, 
2H), 4.10–3.90 (m, 2H), 2.56–2.42 (m, 1H), 2.38 (s, 3H), 2.33 (s, 3H), 1.02 (d, 3H, J = 6.4 Hz),  
0.81 (d, 3H, J = 6.4 Hz); 
13
C-NMR: δ (ppm) 170.9, 166.1, 165.4, 162.6, 136.7, 133.1, 133.0, 128.9, 
128.7, 117.4, 100.6, 42.6, 26.5, 26.1, 24.1, 19.9, 19.1; IR (thin film): 2968, 1671, 1583, 1535, 1474, 
1403, 1339, 1268, 1203, 1085 cm
−1
; HRMS: Calcd. for C21H27ClN4O: 386.1873, Found: 386.1868. 
Ethyl 3-(7-(1-(cyclohexylcarbamoyl)propyl)-6,7-dihydro-2,4-dimethyl-5H-pyrrolo[2,3-d]pyrimidin-5-
yl)propanoate (2a). Yellow liquid, (200 mg, 48%), 
1
H-NMR: δ (ppm) 6.43 (d, 1H, J = 7.5 Hz), 4.40  
(t, 1H, J = 7.7 Hz), 4.06 (q, 2H, J = 6.8 Hz), 3.80–3.63 (m, 2H), 3.40–3.25 (m, 2H), 2.45 (s, 3H),  
2.34–2.20 (m, 5H), 2.10–1.95 (m, 2H), 1.90–1.70 (m, 4H), 1.69–1.46 (m, 3H), 1.40–1.05 (m, 8H),  
0.88 (t, 3H, J = 7.3 Hz); 
13
C-NMR: δ (ppm) 172.8), 169.1, 166.3, 166.2, 157.2, 116.4, 60.6, 57.9, 50.5, 
47.8, 35.0, 32.9, 32.8, 30.4, 28.9, 25.8, 25.4, 24.5, 24.4, 20.8, 20.5, 14.2, 10.7; IR (thin film): 2929, 
2855, 2356, 1731, 1657, 1609, 1570, 1517, 1448, 1400, 1312, 1277, 1260, 1168, 1168, 1089, 1028 cm
−1
; 
HRMS: Calcd. for C23H36N4O3: 416.2787, Found: 416.2767. 
Ethyl 3-(1-(1-(cyclohexylcarbamoyl)-3-methylbutyl)-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-
propanoate (2b). Pale yellow liquid, ( 100 mg, 24%), 
1
H-NMR: δ (ppm) 8.21 (s, 1H), 8.12 (d, 1H,  
J = 5.8 Hz), 6.55 (d, 1H, J = 5.8 Hz), 6.04 (br s, 1H), 4.10 (q, 2H, J = 7.1 Hz), 3.93 (t, 1H, J = 6.5 Hz), 
3.80–3.60 (m, 3H), 3.00–2.88 (m, 1H), 2.29 (t, 2H, J = 7.0 Hz), 2.02 (dd, 1H, J = 7.0, 13.4 Hz),  
1.95–1.78 (m, 4H), 1.74–1.50 (m, 6H), 1.35–1.15 (m, 11H), 0.95–0.82 (m, 2H); 
13
C-NMR: δ (ppm) 
173.0, 171.1, 148.1, 147.6, 146.1, 127.0, 107.0, 60.4, 60.2, 49.3, 48.2, 39.6, 33.7, 33.0, 32.8, 30.3, 
30.0, 29.0, 25.3, 24.8, 24.7, 24.5, 22.2, 14.1; IR (thin film): 2924, 2840, 2361, 1727, 1644, 1660, 1517, 
1448, 1374, 1277, 1260, 1163, 1098, 1064, 1028 cm
−1
; HRMS: Calcd. for C24H37N3O3: 415.2835, 
Found: 415.2837. 
Ethyl 3-(1-(1-(tert-butylcarbamoyl)-3-methylbutyl)-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-
propanoate (2c). Pale brown liquid, (85 mg, 27%), 
1
H-NMR: δ (ppm) 8.23 (s, 1H), 8.14 (d, 1H,  
J = 5.8 Hz), 6.55 (d, 1H, J = 5.8 Hz), 5.85 (br s, 1H), 4.10 (q, 2H, J = 7.1 Hz), 3.82 (t, 1H, J = 6.5 Hz), 
3.74–3.62 (m, 2H), 3.00–2.87 (m, 1H), 2.30 (t, 2H, J = 7.0 Hz), 2.26–2.17 (m, 1H), 2.06–196 (m, 1H), 
1.94–1.83 (m, 1H), 1.65–1.55 (m, 2H), 1.32 (s, 9H), 1.31–1.18 (m, 9H); 
13
C-NMR: δ (ppm) 173.0, 
171.1, 156.2, 148.0, 146.7, 127.4, 107.0, 60.9, 60.4, 51.2, 49.4, 39.6, 33.8, 33.3, 30.3, 28.5, 24.6, 22.2, 
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14.2;. IR (thin film): 2960, 2933, 2361, 1727, 1666, 1596, 1543, 1505, 1448, 1365, 1277, 1255, 1220, 
1163 cm
−1
; HRMS: Calcd. for C22H35N3O3: 389.2678, Found: 389.2679. 
Ethyl 3-(7-(1-(cyclohexylcarbamoyl)propyl)-6,7-dihydro-4-methyl-2-phenyl-5H-pyrrolo[2,3-d]-
pyrimidin-5-yl)propanoate (2d). Pale yellow liquid, (265 mg, 55%), 
1
H-NMR: δ (ppm) 8.40–8.30 (m, 
2H), 7.54–7.38 (m, 3H), 6.52 (br s, 1H), 4.63–4.45 (m, 1H), 4.09 (q, 2H, J = 7.0 Hz), 3.80–3.60 (m, 
2H), 3.50–3.25 (m, 2H), 2.40 (s, 3H), 2.37–2.24 (m, 2H), 2.18–1.96 (m, 2H), 1.94–1.70 (m, 4H),  
1.63–1.38 (m, 3H), 1.34–1.14 (m, 6H), 1.05–0.80 (m, 5H); 
13
C-NMR: δ (ppm) 172.8, 169.3, 166.6, 
163.0, 157.9, 138.2, 130.0, 128.2, 127.7, 117.5, 60.6, 58.2, 50.7, 47.9, 35.2, 32.8, 32.7, 30.4, 28.8, 
25.3, 24.4, 24.2, 21.0, 20.9, 14.2, 10.8; IR (thin film): 2972, 2929, 2850, 1731, 1662, 1605, 1562, 
1531, 1452, 1377, 1312, 1246, 1163 cm
−1
,
 
HRMS: Calcd. for C28H38N4O3: 478.2944, Found: 
478.2950. 
N-Cyclohexyl-2-(5,6-dihydro-4-methyl-5-(3-oxobutyl)-2-phenylpyrrolo[2,3-d]pyrimidin-7-yl)butan-amide 
(2e). Yellow liquid, (75 mg, 44%), 
1
H-NMR: δ (ppm) 8.40–8.25 (m, 2H), 7.55–7.35 (m, 3H), 6.50 (d, 
1H, J = 8.0Hz), 4.50 (t, 1H, J = 6.6 Hz), 3.78–3.58 (m, 2H), 3.45–3.25 (m, 2H), 2.47 (t, 2H, J = 7.5 Hz), 
2.40 (s, 3H), 2.16–2.00 (m, 5H), 1.90–1.66 (m, 4H), 1.60–1.34 (m, 4H), 1.30–1.14 (m, 2H), 1.10–0.85 
(m, 5H); 
13
C-NMR: δ (ppm) 207.9, 169.3, 166.5, 162.9, 157.8, 138.1, 130.0, 128.2, 127.7, 117.7, 58.2, 
51.2, 47.8, 39.4, 35.1, 32.7, 30.0, 27.4, 25.3, 24.4, 24.3, 21.1, 21.0, 10.8; IR (thin film): 2929, 2853, 
1710, 1656, 1603, 1564, 1508, 1454, 1377, 1317, 1247, 1159, 1064 cm
−1
, HRMS: Calcd. for 
C27H36N4O2: 448.2838, Found: 448.2836. 
Ethyl 3-(7-(N-p-tolylmethan-carbamoylmethyl)-6,7-dihydro-4-methyl-2-phenyl-5H-pyrrolo[2,3-d]-
pyrimidin-5-yl)propanoate (2f). Pale yellow liquid, (125 mg, 27%), 
1
H-NMR: δ (ppm) 8.28 (d, 2H,  
J = 7.6 Hz), 7.45–7.34 (m, 3H), 7.10 (d, 2H, J = 7.6 Hz), 7.00 (d, 2H, J = 7.6 Hz), 6.95 (br s, 1H), 
4.50–4.25 (m, 3H), 4.08–3.95 (m, 3H), 3.75–3.65 (m, 1H), 3.45–3.35 (m, 2H), 2.40 (s, 3H), 2.33–2.20 
(m, 5H), 2.10–2.00 (m, 1H), 1.96–1.85 (m, 1H), 1.20 (t, 3H, J = 7.0 Hz); 
13
C-NMR: δ (ppm) 173.0, 
169.0, 167.0, 163.6, 158.5, 138.0, 137.1, 135.0, 130.1, 129.4, 128.3, 128.0, 127.6, 117.4, 60.8, 55.8, 
49.5, 43.2, 35.8, 30.8, 28.7, 21.1, 21.0, 14.2; IR (thin film): 2924, 2356, 1731, 1662, 1605, 1583, 1570, 
1518, 1448, 1377, 1325, 1260, 1172, 1024 cm
−1
, HRMS: Calcd. for C28H32N4O3: 472.2474, Found : 
472.2473. 
Ethyl 3-(1-(1-(cyclohexylcarbamoyl)propyl)-2,3-dihydro-5-nitro-1H-pyrrolo[2,3-b]pyridin-3-yl)-
propanoate (2g). Pale brown liquid, (297 mg, 48%), 
1
H-NMR: δ (ppm) 8.86 (s, 1H), 7.92 (s, 1H),  
6.04 (br s, 1H), 4.05 (t, 1H, J = 7.5 Hz), 4.15 (q, 2H, J = 7.2 Hz), 4.00–3.83 (m, 1H), 3.79–3.62 (m, 
1H), 3.55–3.30 (m, 2H), 2.44–2.30 (m, 2H), 2.20–1.98 (m, 2H), 1.94–1.76 (m, 3H), 1.74–1.64 (m, 
3H), 1.62–1.50 (m, 2H), 1.34–1.25 (m, 6H), 1.20–1.10 (m, 1H), 0.95 (t, 3H, J = 7.2 Hz); 
13
C-NMR: δ 
(ppm) 172.5, 168.1, 164.6, 146.7, 136.6, 126.7, 125.7, 60.8, 58.5, 51.9, 48.2, 36.2, 33.0, 31.0, 30.9, 
29.5, 25.4, 24.6, 24.5, 21.4, 14.3, 10.7; I.R. (thin film): 2933, 2850, 2356, 1731, 1657, 1609, 1574, 
1517, 1496, 1443, 1377, 1291, 1186, 1090, 1024 cm
−1
, HRMS: Calcd. for C22H32N4O5: 432.2373,  
Found: 432.2386. 
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N-Cyclohexyl-2-(5,6-dihydro-2,4-dimethyl-5-(3-oxo-3-phenylpropyl)pyrrolo[2,3-d]pyrimidin-7-yl)-
butanamide (2h). Pale brown liquid, (150 mg, 34%), 
1
H-NMR: δ (ppm) 7.90 (d, 2H, J = 7.8 Hz),  
7.58–7.54 (m, 1H), 7.48–7.41 (m, 2H), 6.48 (d, 1H, J = 7.8 Hz), 4.41 (t, 1H, J = 7.7 Hz), 3.80–3.65 (m, 
2H), 3.46–3.30 (m, 2H), 3.08–2.83 (m, 2H), 2.45 (s, 3H), 2.30 (s, 3H), 2.26–2.14 (m, 1H), 2.08–1.96 
(m, 1H), 1.94–1.40 (m, 7H), 1.30–0.98 (m, 5H), 0.90 (t, 3H, J = 7.3 Hz); 
13
C-NMR: δ (ppm) 199.3, 
169.2, 166.3, 166.1, 157.2, 136.6, 133.2, 128.6, 127.9, 116.8, 58.0, 50.7, 47.9, 35.2, 34.1, 33.0, 32.8, 
28.2, 25.8, 25.4, 24.4, 21.1, 20.6, 10.8; IR (thin film): 2929, 2853, 1671, 1611, 1568, 1515, 1446, 1404, 
1358, 1317, 1270, 1259, 1202, 1083 cm
−1
, HRMS: Calcd. for C27H36N4O2: 448.2838, Found: 448.2843. 
Ethyl 3-(7-(1-(4-chlorobenzylcarbamoyl)-2-methylpropyl)-6,7-dihydro-2,4-dimethyl-5H-pyrrolo[2,3-
d]pyrimidin-5-yl)propanoate (2i). Pale yellow liquid, (203 mg, 43%), 
1
H-NMR: δ (ppm) 7.22 (d, 2H,  
J = 8.0 Hz), 7.07 (d, 2H, J = 8.0 Hz), 6.97 (d, 1H, J = 6.0 Hz), 4.39 (dd, 2H, J = 6.0, 14.7 Hz), 4.12 (q, 
2H, J = 7.0 Hz), 4.04–3.97 (m, 1H), 3.73 (t, 1H, J = 7.0 Hz), 3.40–3.20 (m, 2H), 2.51–2.38 (m, 1H), 
2.35 (s, 3H), 2.28 (s, 3H), 2.23 (t, 2H, J = 7.5 Hz), 2.10–1.90 (m, 1H), 1.80–1.65 (m, 1H), 1.25 (t, 3H, 
J = 7.0 Hz), 1.00 (d, 3H, J = 7.0 Hz), 0.87 (d, 3H, J = 7.0 Hz); 
13
C-NMR: δ (ppm) 172.8, 169.6, 166.1, 
165.9, 157.3, 136.7, 133.2, 128.9, 128.7, 116.6, 64.0, 60.6, 51.5, 42.6, 35.2, 30.6, 28.9, 26.4, 25.7, 
20.6, 19.5, 19.1, 14.2; IR (thin film): 2964, 2924, 1731, 1671, 1609, 1570, 1531, 1469, 1403, 1273, 
1177, 1094, 1011 cm
−1
, HRMS: Calcd. for C25H33ClN4O3: 472.2241, Found : 472.2244. 
4. Conclusions 
The reported two-step cascade constitutes a concise entry into pyrrolidino- pyridines and 
pyrimidines. Compared with previous results obtained on xanthate cascades performed on  
N-allylamino- pyridine and pyrimidines, these new couplings significantly widen the scope of these 
reactions. The modest efficiency of the whole process is counter-balanced by the simple experimental 
procedure and the straightforward access to important biologically relevant scaffolds [40-43]. This 
work is a new example of the potential of radical chemistry in Ugi post-condensations. 
Acknowledgements 
P. P. thanks the ANR-CP2D Program (ANR MUSE) for a fellowship. 
References and Notes 
1. Dömling, A. Recent Developments in Isocyanide Based Multicomponent Reactions in Applied 
Chemistry. Chem. Rev. 2006, 106, 17-89 and references cited therein. 
2. Dömling, A.; Ugi, I. Multicomponent reactions with isocyanides. Angew. Chem. Int. Ed. 2000, 39, 
3168-3210. 
3. Lu, K.; Luo, T.; Xiang, Z.; You, Z.; Fathi, R.; Chen, J.; Yang, Z. A Concise and Diversity-
Oriented Strategy for the Synthesis of Benzofurans and Indoles via Ugi and Diels-Alder 
Reactions. J. Comb. Chem. 2005, 7, 958-967. 
4. Paulvannan, K. An Atom-Economical approach to Conformationally Constrained Tricyclic 
Nitrogen Heterocycles via Sequential and tandem Ugi/Intramolecular Diels-Alder Reaction of 
Pyrrole. J. Org. Chem. 2004, 69, 1207-1214. 
Molecules 2011, 16 9271 
 
 
5. Akritopoulou-Zanze, I.; Djuric, S.W. Synthesis of novel fused isoxazoles and isoxazolines by 
sequential Ugi/INOC reactions. Tetrahedron Lett. 2004, 45, 3421-3423. 
6. Akritopoulou-Zanze, I.; Gracias, V.; Djuric, S.W. A versatile synthesis of fused triazolo 
derivatives by sequential Ugi/alkyne–azide cycloaddition reactions. Tetrahedron Lett. 2004, 45, 
8439-8441. 
7. Akritopoulou-Zanze, I.; Whitehead, A.; Waters, J.E.; Henry, R.F.; Djuric, S.W. Synthesis of 
Novel and Uniquely Shaped 3-Azabicyclo[4.2.0]octan-4-one Derivatives by Sequential Ugi/[2 + 
2] Ene-Enone Photocycloadditions. Org. Lett. 2007, 9, 1299‐1302. 
8. Akritopoulou-Zanze, I.; Wang, Y.; Zhao, H.; Djuric, S.W. Synthesis of substituted fused 
pyridines, pyrazines and pyrimidines by sequential Ugi/inverse electron demand Diels–Alder 
transformations. Tetrahedron Lett. 2009, 50, 5773-5776. 
9. Fayol, A.; Zhu, J. Multicomponent synthesis of epoxy-tetrahydronaphthyridine and structural 
diversification by subsequent fragmentation. Tetrahedron 2005, 61, 11511-11519. 
10. Gracias, V.; Moore, J.D.; Djuric, S.W. Sequential Ugi/Heck cyclization strategies for the facile 
construction of highly functionalized N-heterocyclic scaffolds Tetrahedron Lett. 2004, 45, 417-420. 
11. Xiang, Z.; Luo, T.; Lu, K.; Cui. J.; Shi, X.; Fathi, R.; Chen, J.; Yang, Z. Concise Synthesis of 
Isoquinoline via the Ugi and Heck Reactions. Org. Lett. 2004, 6, 3155-3158. 
12. Krelaus, R.; Westermann, B. Preparation of peptide-like bicyclic lactams via a sequential Ugi 
reaction-olefin metathesis approach. Tetrahedron Lett. 2004, 45, 5987-5990. 
13. Kazmaier, U.; Hebach, C.; Watzke, A.; Maeir, S.; Mues, H.; Huch, V. A straightforward approach 
towards cyclic peptides via ring-closing metathesis-scope and limitations. Org. Biomol. Chem. 
2005, 3, 136-145. 
14. Basso, A.; Banfi, L.; Riva, R.; Guanti, G. Preparation of optically pure fused polycyclic scaffolds 
by Ugi reaction followed by olefin and enyne metathesis. Tetrahedron 2006, 62, 8830-8837. 
15. Kalinski, C.; Umkehrer, M.; Ross, G.; Kolb, J.; Burdack, C.; Hillerb, W. Highly substituted indol-
2-ones, quinoxalin-2-ones and benzodiazepin-2,5-diones via a new Ugi(4CR)-Pd assisted N-aryl 
amidation strategy. Tetrahedron Lett. 2006, 47, 3423-3426. 
16. Marcaccini, S.; Miliciani, M.; Pepino, R. A facile synthesis of 1,4-benzodiazepine derivatives via 
Ugi four-component condensation .Tetrahedron Lett. 2005, 46, 711-713. 
17. Nixey, T.; Tempest, P.; Hulme, C. Two-step solution-phase synthesis of novel quinoxalinones 
utilizing a UDC (Ugi/de-Boc/cyclize) strategy. Tetrahedron Lett. 2002, 43, 1637-1639. 
18. Banfi, L.; Basso, A.; Casuscelli, F.; Guanti, G.; Naz, F.; Riva, R.; Zito, P. Synthesis of Novel 
Isochromene Derivatives by Tandem Ugi Reaction/Nucleophilic Substitution. Synlett 2010, 85-88. 
19. Ignacio, J.M.; Macho, S.; Marcaccini, S.; Pepino, R.; Torroba, T. A Facile Synthesis of 1,3,5-
Trisubstituted Hydantoins via Ugi Four-Component Condensation. Synlett 2005, 2005, 3051-3054. 
20. Xing, X.; Wu, J.; Luo, J.; Dai, W.-M. C-N Bond-Linked Conjugates of Dibenz[b,f][1,4]oxazepines 
with 2-Oxindole. Synlett 2006, 2099-2103. 
21. Nixey, T.; Kelly, M.; Semin, D.; Hulme, C. Short solution phase preparation of fused azepine-
tetrazoles via a UDC (Ugi/de-Boc/cyclize) strategy. Tetrahedron Lett. 2002, 43, 3681-3684. 
22. El Kaim, L.; Grimaud, L.; Miranda, L.D.; Vieu, E. Ugi/xanthate cyclizations as a radical route to 
lactam scaffolds. Tetrahedron Lett. 2006, 47, 8259-8261. 
Molecules 2011, 16 9272 
 
 
23. El Kaim, L.; Grimaud, L.; Miranda, L.D.; Vieu, E. From Simple Ugi Adducts to Indane and delta-
Amidomalonate: New Mn(OAc)3 Induced Radical Cascades. Org. Lett. 2007, 9, 4171-4173. 
24. Zamudio-Medina, A.; García-González, M.C.; Padilla, J.; González-Zamora, E. Synthesis of a 
tetracyclic lactam system of Nuevamine by four-component reaction and free radical cyclization. 
Tetrahedron Lett. 2010, 51, 4837-4839. 
25. El Kaim, L.; Grimaud, L.; Miranda, L.D.; Vieu, E.; Cano-Herrera, M.-A.; Perez-Labrada, K. New 
xanthate-based radical cyclization onto alkynes. Chem. Commun. 2010, 46, 2489-2491. 
26. Gámez-Montaño, R.; Ibarra-Rivera, T.; El Kaim, L.; Miranda, L.D. Efficient Synthesis of 
Azaspirodienones by Microwave-Assisted Spirocyclization of Xanthate-Containing Ugi Adducts. 
Synthesis 2010, 8, 1285-1290. 
27. Yu, H.; Gai, T.; Sun, W.L.; Zhang, M.S. Radical reduction of Passerini 3CR adducts by 
SmI2/HMPA. Chin. Chem. Lett. 2011, 22, 379-381. 
28. Zard, S.Z. On the Trail of Xanthates: Some New Chemistry from an old Functional Group. 
Angew. Chem. Int. Ed. Engl. 1997, 36, 672-685. 
29. Quiclet-Sire, B.; Zard, S.Z. The Degenerative Radical Transfer of Xanthates and Related 
Derivatives: An Unusually Powerful Tool for the Creation of Carbon–Carbon Bonds. Top. Curr. 
Chem. 2006, 264, 201-236. 
30. Ly, T.-L.; Quiclet-Sire, B.; Sortais, B.; Zard, S.Z. A Convergent Approach to Indolines and 
Indanes. Tetrahedron Lett. 1999, 40, 2533-2536. 
31. Bacqué, E.; El Qacemi, M.; Zard, S.Z. Tin-Free Radical Cyclizations for the Synthesis of 7-
Azaoxindoles, 7-Azaindolines, Tetrahydro[1,8]naphthyridines, and Tetrahydro-5H-pyrido[2,3-
b]azepin-8-ones. Org. Lett. 2004, 6, 3671-3674. 
32. El Qacemi, M.; Ricard, L.; Zard, S.Z. An unprecedented radical ring closure on a pyridine 
nitrogen. Chem. Commun. 2006, 4422-4424. 
33. Laot, Y.; Petit, L.; Zard, S.Z. Unusual radical addition on a heteroaromatic nitrogen. A convenient 
access to new pyrimidine derivatives. Chem. Commun. 2010, 46, 5784-5786. 
34. Laot, Y.; Petit, L.; Zard, S.Z. Synthesis of Fluoroazaindolines by an Uncommon Radical ipso 
Substitution of a Carbon-Fluorine Bond. Org. Lett. 2010, 12, 3426-3429. 
35. Laot, Y.; Petit, L.; Diem My Tran, N.; Zard, S.Z. Fluoroazaindolines by an Uncommon Radical 
ipso-Substitution of a Carbon-Fluorine Bond. Aust. J. Chem. 2011, 64, 416-425. 
36. El Kaim, L.; Grimaud, L.; Oble, J. Phenol Ugi–Smiles Systems: Strategies for the 
Multicomponent N-Arylation of Primary Amines with Isocyanides, Aldehydes, and Phenols. 
Angew. Chem. Int. Ed. 2005, 44, 7961-7964. 
37. El Kaim, L.; Gizolme, M.; Grimaud, L.; Oble, J. Smiles Rearrangements in Ugi- and Passerini-
Type Couplings: New Multicomponent Access to O- and N-Arylamides. J. Org. Chem. 2007, 72, 
4169-4180. 
38. El Kaim, L.; Gizolme, M.; Grimaud, L.; Oble, J. Direct Access to Heterocyclic Scaffolds by New 
Multicomponent Ugi-Smiles Couplings. Org. Lett. 2006, 8, 4019-4021. 
39. The structure of the major diastereomers could not be determined with usual NMR techniques. 
40. Aso, K.; Kobayashi, K.; Mochizuki, M.; Kanzaki, N.; Sako, Y.; Yano, T. Discovery of 
pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a 
carbonyl-based hydrogen bonding acceptor. Bioorg. Med. Chem. Lett. 2011, 21, 2365-2371. 
Molecules 2011, 16 9273 
 
 
41. Mueller, C.E.; Geis, U.; Grahner, B.; Lanzner, W.; Eger, K. Chiral Pyrrolo[2,3-d]pyrimidine  
and Pyrimido[4,5-b]indole Derivatives: Structure-Activity Relationships of Potent, Highly 
Stereoselective A1-Adenosine Receptor Antagonists. J. Med. Chem. 1996, 39, 2482-2491. 
42. Aso, K.; Hitaka, T.; Yukishige, K.; Ootsu, K.; Akimoto, H. Synthesis and Antitumor Activity of 
Pyrrolo[2,3-d]pyrimidine Antifolates with a Bridge Chain Containing a Nitrogen Atom. Chem. 
Pharm. Bull. 1995, 43, 256-261. 
43. Simard, D.; Leblanc, Y.; Berthelette, C.; Zaghdane, M.H.; Molinaro, C.; Wang, Z.; Gallant, M.; 
Lau, S.; Thao, T.; Hamel, M.; Stocco, R.; Sawyer, N.; Sillaots, S.; Gervais, F.; Houle, R.; 
Levesque, J.-F. Azaindoles as potent CRTH2 receptor antagonists. Bioorg. Med. Chem. Lett. 
2011, 21, 841-845. 
Sample Availability: Not available. 
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
